KTOS, OXGN, SWKS, – PennyToBuck.com Watch List For Friday Nov. 4th, 2011
pennytobuck Newsletter
__ KTOS, Kratos Defense & Security Solutions, Inc.
** On its third quarter fiscal 2011, KTOS posted revenues of $211.0 million, a 75.97% increase compared to revenues of $119.9 million in the same period a year ago. For the fourth quarter, KTOS is forecasting revenues to increase to approximately $230 to $240 million.
KTOS is a specialized National Security Technology business providing mission critical products, services and solutions for United States National Security priorities.
More about KTOS at www.KratosDefense.com.
******************
SWKS, Skyworks Solutions, Inc.
** SWKS delivered $402.3 Million in revenue for the fourth fiscal quarter 2011, up 28% year-over-year and 13% sequentially. For fiscal year 2011, revenue was $1.419 billion versus $1.072 billion in fiscal 2010, a 32% increase.
According to the company`s first fiscal quarter 2012 outlook, SWKS expects revenue in the period to be up 16% year-over-year in the $390 million range.
SWKS is an innovator of high reliability analog and mixed signal semiconductors. Leveraging core technologies, SWKS offers diverse standard and custom linear products supporting automotive, broadband, cellular infrastructure, energy management, industrial, medical, military and mobile handset applications.
More about SWKS at www.skyworksinc.com.
******************
OXGN, OXiGENE, Inc.
** OXGN reported final results from the FALCON trial, a stratified, randomized, controlled Phase 2 study of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) in patients with advanced non-small cell lung cancer.
.
The final analysis of the data showed that the combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT arm) was observed to be well-tolerated with no significant cumulative toxicities or overlapping toxicities with bevacizumab when compared with the control arm of the study (standard chemotherapy plus bevacizumab). In addition, an analysis of patients with tumor burden greater than 10 cm suggested meaningful improvements in overall survival for patients receiving ZYBRESTAT in addition to bevacizumab and chemotherapy. For patients with this large tumor burden, median overall survival was 14.2 months, compared with 11.0 months for patients on the control arm of the study. For the overall patient population, no survival benefit was observed for patients receiving ZYBRESTAT.
OXGN believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.
OXGN is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. OXGN`s major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.
More about OXGN at www.oxigene.com ********************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.
— The following information is a reminder of your current mailing list subscription:
You are subscribed to the following list:
pennytobuck.com
Related posts:
- SWKS, OXGN, KTOS, – Stock-PR.com Stock Watch For Friday Nov. 4th, 2011
- KTOS, OXGN, SWKS, – CRWESelect.com Stocks To Watch For Friday Nov. 4th, 2011
- OXGN, KTOS, SWKS, – DoubleInStocks.com Stock Watch For Friday Nov. 4th, 2011
- SWKS, CBI, PMCS, – PennyToBuck.com Watch List For Friday July 22nd